Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study

ABSTRACT:

Background:

Vedolizumab is a gut-selective anti-lymphocyte trafficking agent used to

SUBMITTER:  

PROVIDER: S-EPMC9932778 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature